THE DEAL, AT A GLANCE
2/4 reviewedRivercell
Rivercell
Rivercell builds a cell model that predicts how human cells respond to drugs and genes.
Rivercell raised $25M Series B01What it doesRivercell builds a cell model that predicts how human cells respond to drugs and genes.Source-grounded · automated review · Explore ↗
Checked 2026-10-08 · Review due 2026-10-15
Read supporting source ↗Rivercell builds a proprietary platform…
02Who is involvedBacked by HV, HCVC, Alven, Bpifrance Digital VentureFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedRivercell raised $25M Series BFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersIts system could reduce some physical lab experiments by predicting cell reactions in software.Interpretation · Explore ↗
Checked 2026-10-08 · Review due 2026-10-15
Read supporting source ↗Their platform captures interventional, time-resolved,…
Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗
Rivercell · Financing Record
Explore source-linked visual explanations for Rivercell. Unsupported claims are withheld while source review continues.
Record 13607 · Recorded date: Needs review
Explore company records →